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Depression is one of the most common mental disorders worldwide. According to the World
Health Organization, it is estimated that nearly 280 million people are affected worldwide.
The factors that contribute to the development of depression are complex and include
social, psychological, and biological components. It has been known to have a negative effect
on a person’s quality of life, sleep, concentration, physical health, and relationships. The
2020 National Survey on Drug Use and Health from the NIH estimates that around 21.0
million American adults (8.4%) have experienced at least one depressive episode in the last
year. The incidence in college-age adults 18-25 years of age was even higher at 17.0%.

To increase the ketamine-like effect in our previously synthesized analogs, we examined
known AMPA potentiators and compared them to the structure of MI-4. This was done using
a combination of both molecular overlays as well as pharmacophore analysis.

The synthesized compounds and their respective parent analogs were tested against
paroxetine and desipramine. The two TR-11 analogs (TR-18 and TR-19) maintained or
improved upon the inhibition of SERT, while the TR-2 analogs (TR-20 and TR-21) both lost
the inhibition of SERT and notably, TR-20 acted as a strong SERT agonist instead of
antagonist. Compared to previous experiments, the measured SERT inhibition of paroxetine,
desipramine, MI-4, and TR-11 was lower than previous measurements. This could be due to
the age of the uptake assay kit, or the cell lines, and these experiments will be redone.

Figure 3.

( https://www.nimh.nih.gov/health/statistics/major-depression; accessed 3/22/2022)
Figure 1.

The molecular overlay of MI-4 and both TAK-137 and paroxetine were performed to identify
places to modify MI-4 to potentiate AMPA receptors without negatively affecting the
monoamine transport inhibition. One of our findings was that TAK-137 has hydrogen-bond
accepting capability around the sulfonamide group, and the phenol on MI-4 could also be
acting as a hydrogen-bond acceptor. Through further examination of paroxetine, we could
see that the methylenedioxy (MD) group found in paroxetine could substitute for the phenol
on MI-4 and perhaps give more opportunities for hydrogen bonds to form.
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Adapted from Duman, RS; Voleti, B. Trends in Neuroscience 2012, 35(1), 47-56.

Depression is commonly treated with monoamine reuptake inhibitors such as SSRIs or SNRIs
that regulate the neurotransmitters in the synaptic cleft of the neuron. A significant
challenge in the treatment of depression is the delay in the onset of the therapeutic benefit
from currently available anti-depressants. Selective-serotonin reuptake inhibitors (SSRIs) can
take 2-4 weeks to demonstrate efficacy. This delay, coupled with high non-response rates,
necessitates the identification of improved long-lasting anti-depressant medications with
quicker onset of action.

b.

c.

d.

e.

Pharmacophore and molecular overlay analysis of TAK-137 compared to MI-4 and TR-18. a) TAK-137 with
generated pharmacophore. b) pharmacophore: purple-aromatic, green-hydrophobic, blue-hydrogen donor, orangehydrogen acceptor. c) MI-4 overlaid on pharmacophore; note lack of hydrogen acceptor. d) methylenedioxy analog
(TR-18) overlaid on pharmacophore; note oxygen acceptor in orange. e) molecular overlay of TAK-137 and TR-18.

Previously we had studied the antidepressant activity of TR-11. We designed four
compounds (shown below) which were similar in structure to previous TR analogs TR-2 and
TR-11 but contained the desired methylenedioxy group.
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The molecules were synthesized by making the respective amides and reducing them to the
desired amines. These compounds were assayed for purity using a 60 mHz proton NMR and
TLC plating. The synthesis of TR-18 is shown below as an example.

The small molecule ketamine has generated much interest due to its rapid antidepressant
effects. Despite having a rapid onset, ketamine has poor bioavailability, short duration of
action, toxicities with long term use, and high potential for abuse. The molecule MI-4 (RO
25-6981) has also been shown to have both a rapid and sustained antidepressant effect.
Most of the research into the mechanism of the rapid onset of MI-4 and ketamine has
focused on their interaction with the NMDA receptor in addition to some monoamine
transporters. Some recent publications have shown a significant role of AMPA receptors in
the ketamine antidepressant response. Inhibiting the feedback signaling pathway for the
AMPA receptors blocked ketamine activity. The hypothesis is that ketamine or ketamine
metabolites appear to function as AMPA potentiators.

Conclusions
A recent report attributes the antidepressant activity of RO-25-6981 (MI-4) with a
potentiation of the AMPA receptor (Lazarevic et al., Molecular Psychiatry, 2021, 26, 74257435). Using computer modeling, we were able to design several analogs of MI-4 that have
similar shape to known AMPA potentiators and were predicted to maintain inhibitory
properties against the monoamine transporters.
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All four compounds are being tested in wild-type C57BL/6J mice using the tail suspension
and locomotor activity assays which are known models of depression. These results are
currently pending. We have previously seen some antidepressant activity with previous TR
analogs, but they were about 10-fold less potent than MI-4.
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The amount of neurotransmitter uptake was assessed using assay kit from Molecular
Devices. HEK-293 cells were grown to express the serotonin transporter (SERT). These cells
were then incubated for 30 minutes at room temperature in 10 µM of the compounds and
Hank’s Balanced Salt Solution (HBSS). The fluorescent neurotransmitter dye was then added
to the cells and kinetic measurements of the uptake was taken for 30 minutes. These
measurements were then normalized against the number of cells left in each plate well after
staining with crystal violet dye.

The analogs we designed were synthesized and examined in an assay for inhibition of
serotonin transport with varied results. Two of the analogs (TR-18 and TR-19) maintained
inhibition of SERT, and have good overlap with TAK-137, a known potentiator of AMPA (see
Figure 4). Further tests will be performed to measure the inhibition of other monoamine
transporters of these compounds, as well as their ability to serve as antidepressants.
While we have previously reported modest antidepressant activity of some TR analogs, it is
hoped that these analogs could potentiate AMPA better than previous analogs and have
improved antidepressant properties. These experiments will allow us to further understand
the mechanism of action of MI-4 and how the modifications to the molecule may affect
inhibition activity.

